585 related articles for article (PubMed ID: 27684412)
1. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
Crandell JR; Tartaglia C; Tartaglia J
Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412
[TBL] [Abstract][Full Text] [Related]
2. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
Kedia AW; Lynch E
Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
[TBL] [Abstract][Full Text] [Related]
3. Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.
Fialkow J
Am J Cardiovasc Drugs; 2016 Aug; 16(4):229-239. PubMed ID: 27138439
[TBL] [Abstract][Full Text] [Related]
4. Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study.
Crandell JR
Clin Med Insights Cardiol; 2016; 10():123-8. PubMed ID: 27478390
[TBL] [Abstract][Full Text] [Related]
5. Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements.
Reddy KJ; Chowdhury S
Future Cardiol; 2016 May; 12(3):261-8. PubMed ID: 27070379
[TBL] [Abstract][Full Text] [Related]
6. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L
J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081
[TBL] [Abstract][Full Text] [Related]
7. Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl.
Hassan A; Tajuddin N; Shaikh A
Cardiol Ther; 2015 Jun; 4(1):83-93. PubMed ID: 25515964
[TBL] [Abstract][Full Text] [Related]
8. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review.
Jacobson TA; Glickstein SB; Rowe JD; Soni PN
J Clin Lipidol; 2012; 6(1):5-18. PubMed ID: 22264569
[TBL] [Abstract][Full Text] [Related]
9. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA
Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132
[TBL] [Abstract][Full Text] [Related]
10. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia.
Weintraub HS
Postgrad Med; 2014 Nov; 126(7):7-18. PubMed ID: 25387209
[TBL] [Abstract][Full Text] [Related]
11. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
Backes J; Anzalone D; Hilleman D; Catini J
Lipids Health Dis; 2016 Jul; 15(1):118. PubMed ID: 27444154
[TBL] [Abstract][Full Text] [Related]
12. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
Weintraub H
Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771
[TBL] [Abstract][Full Text] [Related]
13. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
Bazarbashi N; Miller M
Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
[TBL] [Abstract][Full Text] [Related]
14. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).
Miller M; Ballantyne CM; Bays HE; Granowitz C; Doyle RT; Juliano RA; Philip S
Am J Cardiol; 2019 Sep; 124(5):696-701. PubMed ID: 31277790
[TBL] [Abstract][Full Text] [Related]
15. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides.
Vijayaraghavan K; Szerlip HM; Ballantyne CM; Bays HE; Philip S; Doyle RT; Juliano RA; Granowitz C
Postgrad Med; 2019 Aug; 131(6):390-396. PubMed ID: 31306043
[No Abstract] [Full Text] [Related]
16. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
Brinton EA; Ballantyne CM; Bays HE; Kastelein JJ; Braeckman RA; Soni PN
Cardiovasc Diabetol; 2013 Jul; 12():100. PubMed ID: 23835245
[TBL] [Abstract][Full Text] [Related]
17. A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients.
Castaldo RS
Postgrad Med; 2014 May; 126(3):268-73. PubMed ID: 24977343
[TBL] [Abstract][Full Text] [Related]
18. Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA).
Brinton EA; Mason RP
Lipids Health Dis; 2017 Jan; 16(1):23. PubMed ID: 28137294
[TBL] [Abstract][Full Text] [Related]
19. Icosapent ethyl: a review of its use in severe hypertriglyceridemia.
Kim ES; McCormack PL
Am J Cardiovasc Drugs; 2014 Dec; 14(6):471-8. PubMed ID: 25428605
[TBL] [Abstract][Full Text] [Related]
20. Omega-3 Fatty Acids Reduce Remnant-like Lipoprotein Cholesterol and Improve the Ankle-Brachial Index of Hemodialysis Patients with Dyslipidemia: A Pilot Study.
Kobayashi Y; Fujikawa T; Haruna A; Kawano R; Ozawa M; Haze T; Komiya S; Suzuki S; Ohki Y; Fujiwara A; Saka S; Hirawa N; Toya Y; Tamura K
Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38256336
[No Abstract] [Full Text] [Related]
[Next] [New Search]
